Fact-checked by Grok 2 weeks ago

Hematemesis

Hematemesis is the medical term for the vomiting of blood or blood-containing material from the upper gastrointestinal tract, typically appearing as bright red blood or dark, coffee-ground-like material due to partial digestion by stomach acid. It is a hallmark symptom of upper gastrointestinal bleeding (UGIB), which originates proximal to the ligament of Treitz in the esophagus, stomach, or duodenum, and often accompanies other signs such as melena (black, tarry stools) or systemic symptoms like orthostasis and fatigue. The condition arises from various underlying etiologies, with accounting for 32-36% of cases, followed by (24%), (18-22%), (13%), and (11%). Other notable causes include Mallory-Weiss tears from prolonged (5-15%), vascular anomalies like Dieulafoy lesions, neoplasms such as esophageal or gastric cancer, and erosive conditions exacerbated by nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, or infection. In patients with , can lead to , while less common triggers encompass clotting disorders, , or swallowed blood from epistaxis. Epidemiologically, UGIB has an annual incidence of 80-150 cases per 100,000 people, predominantly affecting men and increasing with age; it represents about 75% of acute gastrointestinal hemorrhages, though U.S. hospitalization rates declined by 21% from 2002 to 2012. Mortality ranges from 2-10%, underscoring the need for prompt intervention, as significant blood loss can result in , damage, or if untreated. Diagnosis typically involves urgent evaluation with blood tests (e.g., , studies, liver function), nasogastric lavage to confirm upper origin, and (EGD) as the gold standard for identifying the bleeding source. Treatment focuses on hemodynamic stabilization through intravenous fluids, blood transfusions, and acid-suppressive therapy (e.g., inhibitors), with endoscopic interventions like clipping, banding, or for active bleeding; surgery is reserved for refractory cases. The prognosis depends on the and timeliness of care, with many episodes resolving spontaneously but requiring long-term of underlying conditions to prevent recurrence.

Overview

Definition

Hematemesis is defined as the of that originates from the upper , specifically the , , or . This condition involves the regurgitation of fresh or mixed with gastric contents, which can appear if recent or altered due to exposure to . A key feature distinguishing hematemesis from similar presentations is its source: bleeding must arise proximal to the ligament of Treitz, the anatomical boundary marking the transition from the duodenum to the . In contrast, coffee-ground emesis refers to the of partially oxidized , presenting as dark, granular material resembling coffee grounds, which indicates slower or older bleeding within the upper tract. Hematemesis must also be differentiated from , the coughing up of from the lower , as well as from the of swallowed due to epistaxis (nasal bleeding) or , which is the passage of per from lower gastrointestinal sources. Clinically, hematemesis signals active or recent hemorrhage from the and is frequently considered a due to the risk of significant blood loss and hemodynamic instability. It is often associated with underlying conditions such as peptic ulcers.

Epidemiology

Hematemesis represents a prominent manifestation of (UGIB), with global incidence rates for UGIB varying widely from 15 to 172 cases per 100,000 person-years, reflecting differences in diagnostic access and underlying etiologies. In high-income countries, the annual incidence of UGIB is approximately 80 to 150 per 100,000 population, while rates are higher in low- and middle-income countries due to factors such as untreated peptic ulcers and limited healthcare resources. Hematemesis accounts for approximately 30% to 50% of UGIB presentations in adults, often indicating more active or voluminous bleeding compared to alone. Mortality rates for acute UGIB range from 2% to 10% overall, with case-fatality proportions of 0.7% to 4.8%; these figures are higher in low-resource settings, where delays in intervention contribute to poorer outcomes. Patients presenting with hematemesis experience worse short-term outcomes, including a 10-fold higher likelihood of requiring blood transfusions and extended stays averaging 6 additional days, though all-cause mortality differences compared to non-hematemesis UGIB remain statistically imprecise in smaller cohorts. Demographically, hematemesis and UGIB occur more frequently in males, with a male-to-female ratio of about 2:1, attributed to higher rates of behaviors and comorbidities in men. The condition peaks in incidence during ages 50 to 70 years, with over 70% of cases affecting individuals aged 60 or older, as age-related physiological changes and cumulative exposures amplify vulnerability. Major population-level risk factors for hematemesis include a history of prior GI bleeding, which elevates recurrence risk; anticoagulant and antiplatelet therapy, such as or aspirin, increasing odds by 2- to 3-fold; high-dose nonsteroidal anti-inflammatory drugs (NSAIDs); chronic alcohol abuse; infection; and liver , particularly for variceal sources. In elderly populations, —defined as five or more concurrent medications—further heightens susceptibility through drug interactions and cumulative gastrointestinal toxicity. Epidemiological trends show stable or declining UGIB incidence in high-income regions over the past two decades, driven by effective eradication and use, alongside a 21% reduction in hospitalizations from 2002 to 2012. Recent data from 2019 show UGIB incidence increasing to 116.2 per 100,000 after a decline, particularly among the elderly owing to expanded prescriptions and prevalence exceeding 70% in those over 60. Mortality has improved concurrently due to widespread endoscopic therapies, dropping case-fatality rates from 2.6% to 1.9% in monitored cohorts. However, as of 2025, cases are rising among the elderly owing to expanded prescriptions and prevalence exceeding 70% in those over 60, underscoring ongoing challenges in aging populations.

Etiology and Pathophysiology

Causes

The prevalence of causes for hematemesis varies by geographic region and population, with more dominant in Western settings and variceal bleeding higher in areas with prevalent liver disease such as parts of and . Hematemesis, the vomiting of blood, most commonly arises from (UGIB), with representing the leading etiology in adults, accounting for approximately 32% to 50% of cases based on endoscopic evaluations. This includes both gastric and duodenal ulcers, frequently associated with infection, (NSAID) use, or stress-related factors in critically ill patients. Esophageal varices are a major cause of UGIB, comprising 6% to 30% of episodes and ranking as the second most frequent in populations with high rates of liver and , where ruptured varices lead to significant hemorrhage. Mallory-Weiss syndrome, characterized by mucosal tears at the gastroesophageal junction due to forceful or , accounts for 4% to 15% of cases and is often linked to or severe . Erosive conditions such as (18-22%), (24%), and (13%) collectively contribute significantly to hematemesis instances, typically resulting from mucosal due to irritants like NSAIDs, , or acid reflux. Vascular malformations, including Dieulafoy lesions (aberrant submucosal arteries) and , are responsible for about 5% of cases, presenting as sudden, massive bleeding without prior ulceration. Less common etiologies encompass malignancies, such as gastric or (2% to 6%), and rare conditions like aortoenteric fistulas, which may occur post-aortic surgery and carry high mortality. Iatrogenic causes include post-endoscopic bleeding or medication-induced erosions from anticoagulants, antiplatelets, or corticosteroids, exacerbating underlying lesions. Ingested blood from non-gastrointestinal sources, such as epistaxis or oral bleeding, can mimic hematemesis but is distinguished by history and examination. Although the focus remains on adults, pediatric hematemesis etiologies differ, with peptic ulcers (often H. pylori-related), , , and foreign body ingestion or being more prevalent, while are less common unless is present.

Pathophysiology

Hematemesis results from the erosion of blood vessels within the mucosal lining of the upper , primarily due to lesions such as peptic ulcers or . In peptic ulcers, and digest the protective mucosal barrier, exposing underlying submucosal arteries or veins and leading to hemorrhage; arterial erosion typically produces high-pressure, brisk bleeding, while venous involvement results in slower blood loss. , dilated submucosal veins formed in response to , rupture under increased pressure, initiating venous hemorrhage that can rapidly escalate due to the fragile nature of these vessels. Following vessel disruption, blood accumulates in the stomach, where it irritates the and stimulates the vomiting reflex, expelling the contents as hematemesis. Rapid hemorrhage allows for minimal exposure to gastric secretions, resulting in bright red vomitus, whereas slower bleeding permits partial oxidation and digestion of by stomach acid, yielding the dark, coffee-ground appearance characteristic of altered blood. This propagation is confined to the upper gastrointestinal tract proximal to the ligament of Treitz, distinguishing it from lower sources. Hemodynamically, acute blood loss induces , triggering compensatory to maintain ; severe volume depletion (>15% loss) can progress to and shock. In variceal bleeding, —defined by a hepatic venous pressure gradient exceeding 10-12 mm Hg—amplifies the across ruptured vessels, accelerating hemorrhage and worsening . The severity of bleeding is modulated by factors such as vessel caliber, with arterial sources posing greater than venous ones due to higher flow rates. , including common in , impairs initial clot formation, while antiplatelet agents like aspirin exacerbate hemorrhage by inhibiting platelet aggregation and prolonging . Bleeding may initially be occult, detected only through testing, before progressing to overt hematemesis; rebleeding , affecting 10-20% of cases, is heightened by the acidic gastric milieu, which inhibits platelet function, destabilizes clots, and promotes .

Clinical Presentation

Symptoms and Signs

Hematemesis is characterized by the of from the upper , which may appear as indicating fresh, active or as dark, coffee-ground-like material from partially digested . The volume of vomited can range from small streaks mixed with gastric contents to massive amounts exceeding 500 mL, often suggesting significant hemorrhage. Associated symptoms frequently include epigastric pain, particularly in cases related to peptic ulcers, and or preceding the bleed, as seen in Mallory-Weiss tears. Systemic manifestations of , such as , syncope, and , may accompany the primary symptom due to blood loss. In slower bleeds, patients often report , the passage of black, tarry stools, while brisk can lead to , or bright red blood per rectum. Signs of severity encompass hemodynamic instability, including , , , and progression to , reflecting substantial blood volume depletion. Acute presentations typically involve sudden, massive vomiting of bright red blood, as in , whereas chronic hematemesis manifests as recurrent small-volume episodes, often from gastric erosions or neoplasms. Red flags signaling high-risk hematemesis include airway compromise from of , altered mental status due to severe or , and profuse bleeding in patients over 60 years or with comorbidities like .

Hematemesis, the of from an upper gastrointestinal source, must be differentiated from several mimicking conditions to guide appropriate . Common mimics include bleeding, nasopharyngeal sources, and non-hemorrhagic discolorations, each distinguished by clinical history, characteristics, and associated symptoms. Accurate differentiation relies on a thorough history and , as misidentification can lead to delayed treatment of the underlying cause. Respiratory mimics primarily involve , the expectoration of blood from the lungs or bronchi, which can resemble hematemesis but arises from pulmonary such as , , or . typically presents as bright red, frothy blood mixed with , often accompanied by , dyspnea, or , in contrast to the and abdominal discomfort preceding true hematemesis. may contribute to through secondary infection and in the airways, particularly in patients with altered or swallowing difficulties. Key discriminators include the alkaline pH of (due to lack of exposure) versus the acidic pH of hematemesis, as well as the presence of respiratory symptoms over gastrointestinal ones. Non-gastrointestinal sources of apparent hematemesis include epistaxis, where posterior nasal bleeding is swallowed and later vomited, mimicking upper hemorrhage. This is particularly relevant in patients with a history of , , or , and the blood may appear similar to fresh hematemesis without associated symptoms. Oral bleeding from gum disease, dental procedures, or pharyngeal sources can also lead to swallowed blood and subsequent , distinguishable by of the oral and absence of epigastric . These mimics account for a small but notable fraction of cases initially presenting as hematemesis, emphasizing the need for nasal and oropharyngeal inspection. Non-bleeding mimics often involve ingested substances that discolor vomitus, such as red food dyes, beetroot, or certain medications, creating a false appearance of blood without actual hemorrhage. For instance, consumption of beetroot juice can produce red-tinged emesis due to betalain pigments, leading to unnecessary investigations if dietary history is overlooked. These pseudohematemesis cases are benign but require exclusion through patient inquiry about recent intake, as they lack the systemic signs of true bleeding like hemodynamic instability. Gastrointestinal mimics include rare presentations of lower GI bleeding, where massive colonic hemorrhage might reflux into the stomach and be vomited, though this is uncommon and typically accompanied by or rather than isolated hematemesis. Boerhaave syndrome, a spontaneous often following forceful , can present with hematemesis alongside severe and mediastinitis, but it is distinguished by the acute onset after retching and systemic signs of . These conditions highlight the importance of correlating with overall clinical context to avoid with primary upper sources.
FeatureHematemesisHemoptysisEpistaxis (Swallowed)
PresentationVomiting of red or coffee-ground bloodCoughing up frothy, bright red bloodVomiting after swallowing nasal blood
Associated Symptoms, , Dyspnea, , History of , no GI pain
Blood AppearanceAcidic, clotted, mixed with foodAlkaline, foamy, mixed with Fresh red, no froth or food
pHAcidic (gastric)Alkaline (respiratory)Neutral (nasal)
This table summarizes discriminators for common mimics, aiding rapid clinical assessment.

Diagnosis

History and Examination

A thorough is essential in evaluating to determine the acuity, potential etiology, and severity of . Key elements include the onset and characteristics of , such as whether it is sudden or gradual, the volume estimated by the number of episodes or patient description (e.g., cups or bowls full), and the appearance of the blood— suggesting active or coffee-ground material indicating partially digested blood from a slower bleed. Associated symptoms like , , , syncope, or prior similar episodes should be elicited, as these may point to underlying conditions such as or recurrent variceal bleeding. Medication history is critical, particularly the use of nonsteroidal anti-inflammatory drugs (NSAIDs), anticoagulants, antiplatelet agents, or selective serotonin reuptake inhibitors (SSRIs), which increase the risk of mucosal injury or impaired hemostasis. Risk assessment during history-taking involves identifying comorbidities that exacerbate bleeding, such as , , or bleeding diatheses like , as well as lifestyle factors including chronic use or history of , which are associated with variceal hemorrhage. Quantification of blood loss can be approximated by the frequency and volume of vomitus episodes, alongside symptoms of like weakness or orthostasis, to gauge hemodynamic impact. The begins with assessment of to detect instability, including (heart rate >100 beats per minute), (systolic <90 mm Hg), or orthostatic changes indicating significant volume depletion. Abdominal examination should evaluate for tenderness, guarding, or masses suggestive of perforation or tumor, while inspecting for stigmata of chronic liver disease such as spider angiomata, jaundice, ascites, or splenomegaly, which raise suspicion for portal hypertension. Signs of anemia, including pallor, diaphoresis, or cool extremities, are important to note, particularly in ongoing bleeding. Special considerations include ensuring airway patency in patients with massive hematemesis to prevent aspiration, especially during active vomiting, and evaluating neurological status in the elderly, where altered mental status may reflect hypovolemia or comorbidities rather than primary neurologic issues. Severity can be preliminarily assessed using components of risk stratification tools like the , which incorporates elements such as systolic blood pressure, blood urea nitrogen levels, and comorbidities without requiring full computation at the bedside.

Investigations

Laboratory investigations form the initial step in evaluating hematemesis, providing insights into the severity of blood loss, underlying coagulopathy, and potential etiologies such as liver disease. A complete blood count (CBC) assesses for anemia through hemoglobin and hematocrit levels, as well as thrombocytopenia, which may contribute to bleeding risk. Coagulation studies, including prothrombin time (PT), international normalized ratio (INR), and activated partial thromboplastin time (aPTT), are essential to identify coagulopathies, particularly in suspected variceal bleeding associated with liver cirrhosis. Additionally, a basic metabolic panel evaluates blood urea nitrogen (BUN) and creatinine; an elevated BUN relative to creatinine suggests upper gastrointestinal bleeding due to digestion of blood proteins. Liver function tests (LFTs), including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin, help detect hepatic dysfunction that may predispose to portal hypertension and varices. Upper endoscopy, or esophagogastroduodenoscopy (EGD), is the gold standard for diagnosing the source of hematemesis, allowing visualization of the esophagus, stomach, and duodenum to identify lesions such as ulcers, varices, or malignancies. It is recommended to perform EGD within 24 hours of presentation, particularly in hemodynamically stable patients, to confirm the bleeding site and enable immediate biopsy or therapeutic interventions if needed. In high-risk cases with ongoing bleeding or suspected varices, urgent endoscopy within 12 hours may be indicated. Nasogastric lavage involves aspirating gastric contents via a nasogastric tube to confirm the presence of blood, though it has low sensitivity for detecting and is not routinely recommended due to poor diagnostic performance. Fecal occult blood testing, such as guaiac-based stool tests, can detect or occult blood passage, supporting the diagnosis of ongoing . Imaging modalities are reserved for cases where endoscopy is inconclusive or contraindicated. Computed tomography (CT) angiography is useful for identifying vascular abnormalities or obscure bleeding sources, particularly in patients with suspected aortoenteric fistulas or active extravasation. Barium contrast studies are rarely employed due to risks of obscuring endoscopic views but may be considered if endoscopy cannot be performed. Risk stratification tools aid in predicting prognosis and guiding management intensity. The full Rockall score incorporates age, hemodynamic shock, comorbidities, endoscopic diagnosis, and stigmata of recent hemorrhage to estimate rebleeding and mortality risk. The AIMS65 score, based on age greater than 65 years, INR above 1.5, altered mental status, systolic blood pressure below 90 mmHg, and serum albumin below 3 g/dL, effectively predicts in-hospital mortality and resource utilization in upper gastrointestinal bleeding.

Management

Initial Stabilization

Initial stabilization of patients presenting with hematemesis prioritizes the ABC (airway, breathing, circulation) approach to address potential hemodynamic instability and life-threatening complications. The airway should be secured promptly, often requiring endotracheal intubation in cases of massive bleeding or high aspiration risk, to protect against respiratory compromise. Breathing support involves supplemental oxygen to maintain adequate oxygenation, while circulation is established with two large-bore intravenous (IV) lines (≥18-gauge) for rapid fluid and blood product administration. This structured resuscitation aims to restore hemodynamic stability before further diagnostic or therapeutic interventions. Fluid resuscitation begins with intravenous crystalloids, such as normal saline or balanced solutions like lactated Ringer's, administered as boluses to correct hypovolemia and target a systolic blood pressure greater than 90 mmHg. Limited volume replacement is emphasized to avoid over-resuscitation, particularly in suspected variceal bleeding where excessive fluids may exacerbate portal hypertension. In hemodynamically unstable patients, early intensive fluid therapy has been shown to reduce mortality. Blood product administration follows a restrictive transfusion strategy to minimize rebleeding risk. Packed red blood cells should be transfused if hemoglobin is less than 7 g/dL in stable patients without cardiovascular disease, targeting 7-9 g/dL; for those with cardiac conditions, the threshold is less than 8 g/dL. This approach, supported by randomized trials, lowers mortality (relative risk 0.65) and rebleeding rates (relative risk 0.58) compared to liberal transfusion strategies. Fresh frozen plasma or platelets may be given to correct coagulopathy, aiming for platelet counts above 50,000/μL in severe cases. Continuous monitoring of vital signs, including heart rate, blood pressure, and pulse oximetry, is essential during resuscitation, alongside assessment of urine output (target >0.5 mL/kg/hour) to gauge . In patients with , central venous access facilitates pressure monitoring and guides further . Risk stratification tools like the (score ≥6 indicating high intervention risk) aid in identifying those needing intensive care. For suspected variceal hemorrhage, pre-endoscopic administration of —a analog—is recommended to reduce portal pressure and control bleeding. The standard regimen is a 50 mcg intravenous bolus followed by a 50 mcg/hour infusion, continued for up to 5 days or until . This vasoactive , when initiated early, improves in variceal bleeds ( 0.36 for failure to control bleeding).

Medical Therapy

Medical therapy for hematemesis primarily targets through acid suppression, portal pressure reduction in variceal cases, reversal of , and adjunctive measures, administered after initial stabilization to minimize rebleeding risk. For nonvariceal , such as from peptic ulcers, high-dose inhibitors (PPIs) are recommended to promote clot stability by maintaining intragastric above 6. A typical regimen involves intravenous as an 80 mg bolus followed by 8 mg/hour continuous infusion, initiated pre-endoscopically if possible. H2-receptor antagonists serve as an alternative but are less effective than PPIs in reducing rebleeding rates. In variceal hematemesis, often due to in , vasoactive drugs like (1-2 mg IV every 4 hours) or (50 mcg IV bolus followed by 50 mcg/hour infusion) are used to reduce portal pressure and control bleeding, started immediately upon suspicion and continued for 2-5 days alongside endoscopic therapy. Additionally, antibiotic prophylaxis with (1 g IV daily for up to 7 days) is standard to prevent bacterial infections, which occur in up to 50% of cases without prophylaxis and worsen outcomes. Reversal of anticoagulant or antiplatelet effects is crucial in patients on these agents. For warfarin-associated bleeding, intravenous vitamin K (5-10 mg) combined with 4-factor prothrombin complex concentrate (dosed by INR and weight) rapidly corrects coagulopathy. Dabigatran reversal employs idarucizumab (5 g IV), achieving immediate hemostasis in most cases. Platelet transfusions (10-15 mL/kg) address antiplatelet drug effects, particularly in severe thrombocytopenia or ongoing bleeding. Adjunctive therapies include (1 g IV every 6-8 hours for up to 48 hours) as an in select high-risk nonvariceal cases, though routine use is not recommended due to lack of mortality benefit in large trials. Routine prokinetics like erythromycin for gastric emptying are discouraged, as they do not improve outcomes beyond s alone. PPI therapy typically continues for 72 hours post-endoscopy in nonvariceal bleeding, transitioning to oral twice-daily dosing thereafter if is achieved. For peptic ulcer-related hematemesis positive for , long-term eradication with triple or quadruple therapy (e.g., plus two antibiotics for 10-14 days) prevents recurrence, reducing rebleeding risk by over 60% in the first 2.5 years.01386-5/fulltext)

Endoscopic and Surgical Management

Endoscopic management is the cornerstone of definitive for hematemesis, performed after initial stabilization to identify and treat the bleeding source. For patients with high-risk features such as hemodynamic or , urgent upper is recommended within 12 hours of to improve outcomes and reduce rebleeding . In stable patients with nonvariceal , within 24 hours is standard. Therapeutic endoscopic options vary by etiology. For nonvariceal bleeding, such as from peptic ulcers, injection therapy with epinephrine combined with mechanical or thermal methods—such as through-the-scope clips or thermal coagulation using bipolar or heater probes—is preferred to achieve . For variceal bleeding, endoscopic band is the first-line therapy, superior to in controlling acute hemorrhage and preventing rebleeding. These interventions are often supported by pharmacologic adjuncts like inhibitors or vasoactive agents to enhance efficacy. Endoscopic achieves initial success in 80-90% of cases for both nonvariceal and variceal , with rebleeding rates reduced to less than 10% when dual therapy (e.g., injection plus clipping or banding) is employed. If endoscopic therapy fails, surgical intervention is indicated for recurrent exceeding 2 units of blood within 24 hours, ongoing massive hemorrhage, or hemodynamic instability despite resuscitation. Common procedures include oversewing the bleeding ulcer or vessel for nonvariceal sources and portosystemic shunts, such as (TIPS), for refractory variceal to decompress . Interventional radiology serves as a bridge or alternative to , particularly for lesions like Dieulafoy malformations or inaccessible vascular sources. Angiography-guided transcatheter arterial targets the vessel with agents such as coils, achieving technical success in over 90% of cases and clinical success in 70-80%, with lower morbidity than open . Post-procedure care involves close monitoring for complications such as or , with repeat or imaging as needed for suspected rebleeding. As of 2025, advancements like over-the-scope clips have improved outcomes in refractory cases, offering superior tissue approximation and hemostasis rates exceeding 90% for high-risk or recurrent bleeds when standard methods fail.

Prognosis

Outcomes

The overall for patients presenting with hematemesis as a manifestation of (UGIB) ranges from 2% to 10%, with in-hospital mortality estimates typically between 2% and 10% based on recent cohort studies and reviews. for hematemesis are similar to those for other UGIB presentations such as (around 5-10%), though cases with both hematemesis and may have worse outcomes due to more severe , as evidenced by increased rates of transfusion requirements and prolonged stays. is further influenced by advanced age greater than 60 years and the presence of comorbidities such as or renal impairment, which elevate risk through compounded hemodynamic instability. Rebleeding occurs in 10% to 20% of cases within 30 days following initial endoscopic therapy, with the lowest rates observed when hemostasis is successfully achieved endoscopically. Key predictors of rebleeding include peptic ulcer size greater than 2 cm and the presence of a non-bleeding visible vessel on endoscopy, which indicate high-risk stigmata and necessitate aggressive intervention. Factors improving survival include performing endoscopy within 24 hours of presentation, which has been associated with lower in-hospital mortality, reduced morbidity, and shorter length of stay, particularly in non-variceal UGIB. Risk stratification using scoring systems such as the Rockall score further aids prognosis; scores greater than 5 are associated with a mortality risk exceeding 25%, guiding decisions on intensive monitoring and therapy. In the long term, recurrence rates approach 50% within 1 to 2 years if underlying causes like infection remain untreated, underscoring the importance of eradication therapy to prevent repeat episodes. Outcomes have improved as of 2025 with advancements in anticoagulation reversal agents, such as for direct oral anticoagulants, which enhance and reduce bleeding-related mortality in patients on antithrombotic therapy. Special populations face elevated risks; patients with experience mortality rates of 20% to 30% due to variceal bleeding and hepatic , while those in settings exhibit even higher rates owing to multi-organ involvement.

Complications

Hematemesis, as a manifestation of , can lead to a range of acute complications primarily driven by significant blood loss and hemodynamic instability. is a primary concern, occurring when rapid volume depletion impairs tissue perfusion and oxygenation. frequently arises from hypoperfusion secondary to shock, exacerbating morbidity in affected patients. represents another immediate risk, particularly in cases of massive hematemesis where patients may aspirate blood into the airways, with elective for airway protection paradoxically increasing this risk in suspected variceal hemorrhage. Transfusion-related acute lung injury (TRALI) is a notable transfusion-associated complication, especially prevalent in critically ill patients with end-stage undergoing for . Treatment interventions for hematemesis carry their own risks, which can compound the initial insult. Endoscopic therapy, a cornerstone of management, incurs a risk of approximately 1-2% during hemostatic procedures for peptic ulcers. Post-sphincterotomy , associated with (ERCP) in select cases, has an incidence ranging from 3% to 15%. Transcatheter arterial embolization, used for refractory , may result in ischemia, with rates up to 17% reported in gastrointestinal hemorrhage scenarios. In the longer term, recurrent or unresolved hematemesis can precipitate chronic complications, particularly in underlying conditions like . Iron-deficiency anemia develops from ongoing blood loss, leading to fatigue and reduced . Untreated pose a risk of , while hepatic can accelerate in cirrhotic patients, manifesting as worsening liver function and . Systemic effects extend beyond the gastrointestinal tract, with massive bleeding potentially triggering multi-organ failure through profound and inflammatory responses. Electrolyte imbalances, such as , often emerge during aggressive fluid resuscitation efforts. Less common complications include stress ulcers, which may arise from the physiological stress of hospitalization and critical illness, and deep vein thrombosis due to prolonged immobility during recovery.

References

  1. [1]
    Vomiting blood - Mayo Clinic
    Vomiting blood (hematemesis) refers to significant amounts of blood in your vomit. Small streaks or flecks of blood in material you spit up may come from ...Missing: treatment | Show results with:treatment
  2. [2]
    Upper Gastrointestinal Bleeding - StatPearls - NCBI Bookshelf - NIH
    Aug 17, 2024 · Upper gastrointestinal bleeding describes blood loss from a gastrointestinal source localized to the esophagus, stomach, or duodenum, proximal to the ligament ...
  3. [3]
    Vomiting blood Causes - Mayo Clinic
    Vomiting blood may be caused by: Acute liver failure; Aspirin; Benign tumors of the stomach or esophagus; Cirrhosis (scarring of the liver) ...Missing: hematemesis | Show results with:hematemesis
  4. [4]
  5. [5]
    Gastrointestinal Bleeding - StatPearls - NCBI Bookshelf - NIH
    Hematemesis is the regurgitation of blood or blood mixed with stomach contents. Melena is dark, black, and tarry feces that typically has a strong ...
  6. [6]
    Upper Gastrointestinal Bleeding (UGIB) - Medscape Reference
    Sep 1, 2021 · Acute gastrointestinal (GI) bleeding is a potentially life-threatening abdominal emergency that remains a common cause of hospitalization.<|control11|><|separator|>
  7. [7]
    Hematemesis, Melena, and Hematochezia - Clinical Methods - NCBI
    Hematemesis is the vomiting of blood, which may be obviously red or have an appearance similar to coffee grounds. Melena is the passage of black, tarry stools.
  8. [8]
    The global epidemiology of upper and lower gastrointestinal ...
    Apr 27, 2023 · Two studies with large sample sizes reported mortality rates for NVUGIB as 1.1 per 100000 person-years using clinical data from Spain[38] and ...
  9. [9]
    Profile and outcome of patients with upper gastrointestinal bleeding ...
    ... incidence and mortality associated with GI bleeding remains high in limited income countries. In the United States, UGIB accounts for 300,000 admissions per ...
  10. [10]
    Descriptive analysis of common causes of upper gastrointestinal ...
    Mar 10, 2025 · Hematemesis was the predominant presenting feature (57.5%). All patients underwent endoscopy, with a diagnostic yield of 88.4%. Gastric erosion ...
  11. [11]
    Hematemesis is associated with worse outcomes in upper ... - NIH
    Sep 29, 2025 · ABSTRACT. Purpose: To evaluate whether hematemesis is associated with increased morbidity and mortality for upper gastrointestinal bleeding.Missing: incidence prevalence
  12. [12]
    Polypharmacy and Drug-Drug Interactions in Elderly Patients ... - NIH
    Jan 23, 2025 · Approximately 70% of acute upper GI bleeding episodes occur in patients over 60 years of age [17], and the incidence increases with age [18,19].Missing: 2020-2025 | Show results with:2020-2025
  13. [13]
    Upper Gastrointestinal Bleeding in Adults: Evaluation and ... - AAFP
    Mar 1, 2020 · Common risk factors for upper GI bleeding include prior upper GI bleeding, anticoagulant use, high-dose nonsteroidal anti-inflammatory drug use, and older age.Missing: prevalence | Show results with:prevalence
  14. [14]
    update on the management of non-variceal upper gastrointestinal ...
    Mar 20, 2023 · The all-cause upper GI hemorrhage case fatality rate over this same time span decreased from 2.6% to 1.9%, with the largest reductions in ...
  15. [15]
    The prevalence of polypharmacy and hyper ... - Frontiers
    Jun 11, 2024 · The prevalence of polypharmacy was higher among older patients compared to middle-aged patients (73% vs. 62%, p < 0.001). Figure 1 also presents ...Missing: hematemesis | Show results with:hematemesis
  16. [16]
    Diagnosis and Management of Upper Gastrointestinal Bleeding
    Mar 1, 2012 · Peptic ulcer bleeding causes more than 60 percent of cases of upper gastrointestinal bleeding, whereas esophageal varices cause approximately 6 ...
  17. [17]
    Clinical Profile and Endoscopic Findings in Patients with Upper ...
    Peptic ulcer disease was the most common cause of upper GI bleed and was detected in 236 (35.7%) patients in the current study. Whereas, studies by Anand et al.
  18. [18]
    Pediatric Gastrointestinal Bleeding - Medscape Reference
    Apr 17, 2023 · The most common causes of upper GI bleeding in children older than 12 years are duodenal ulcers, esophagitis, gastritis, and Mallory-Weiss tears ...
  19. [19]
    Age-specific causes of upper gastrointestinal bleeding in children
    About three-fourths (73%) of the patients present with hematemesis, followed by melena (21% of patients) and coffee-ground emesis (6% of patients)[1,4].
  20. [20]
  21. [21]
    Management of acute nonvariceal upper gastrointestinal bleeding
    Mar 21, 2012 · A strongly acidic environment leads to inhibition of platelet ... risk for rebleeding and related mortality in patients with high-risk ulcers.
  22. [22]
    Hemoptysis: Diagnosis and Management - AAFP
    Oct 1, 2005 · Differentiating Features of Hemoptysis and Hematemesis ; Absence of nausea and vomiting, Presence of nausea and vomiting ; Lung disease, Gastric ...
  23. [23]
    Pediatric Pulmonary Hemorrhage vs. Extrapulmonary Bleeding in ...
    Oct 23, 2017 · The differential diagnosis between hemoptysis and hematemesis is relatively simple starting from alkaline or acidic pH of the blood-containing ...<|control11|><|separator|>
  24. [24]
    a case report of epistaxis following gastric ulcer - PMC
    Epistaxis can occasionally mimic upper gastrointestinal bleeding; it can be the cause of unexplained hematemesis or melena. A study reported that 0.55% of ...
  25. [25]
    Rare case of beet juice mimicking gastrointestinal bleeding - NIH
    This case highlights the possibility of misinterpreting beet consumption as gastrointestinal bleeding due to their similar color to blood.
  26. [26]
    Boerhaave's syndrome presenting as an upper gastrointestinal bleed
    This case report shows how a common presentation of upper gastrointestinal bleeding can be caused by an atypical presentation of Boerhaave's syndrome.Missing: pseudo food coloring
  27. [27]
    Upper Gastrointestinal Bleeding (UGIB) Clinical Presentation
    Sep 1, 2021 · History findings include weakness, dizziness, syncope associated with hematemesis (coffee ground vomitus), and melena (black stools with a rotten odor).
  28. [28]
    Overview of Gastrointestinal Bleeding - Merck Manuals
    Peptic ulcer, diverticular disease, and angiodysplasia are the most common causes of major bleeding. Variceal bleeding is less common than in younger patients.
  29. [29]
    Gastrointestinal bleeding - Knowledge @ AMBOSS
    May 13, 2025 · Hematemesis: vomiting blood, which can vary in color from bright red to brown and may resemble coffee grounds, depending on the cause. Most ...
  30. [30]
    Expert consensus on emergency diagnosis and treatment...
    Statement 1: Patient consciousness, airway, breathing, and circulation should be evaluated first. If acute upper gastrointestinal bleeding can be preliminarily ...<|control11|><|separator|>
  31. [31]
    Laboratory test variables useful for distinguishing upper from lower ...
    Thus, hemoglobin, TP, LDH, and BUN were useful in the diagnosis of upper vs lower GI bleeding. Consequently, further analyses focused on these four variables.
  32. [32]
    Gastrointestinal bleeding - Diagnosis and treatment - Mayo Clinic
    Oct 13, 2023 · GI bleeding often stops on its own. If it doesn't, treatment depends on where the bleed is from. In many cases, bleeding can be treated with medicine or a ...
  33. [33]
    Role of endoscopy in acute gastrointestinal bleeding in real clinical ...
    In summary, recent guidelines and recent studies suggest that emergency endoscopy should be performed within 12 h if variceal bleeding is present or the ...Role Of Endoscopy In The... · Variceal Bleeding · Endoscopy For Critically Ill...<|control11|><|separator|>
  34. [34]
    Nasogastric aspiration and lavage in emergency ... - PubMed
    According to the included studies, the diagnostic performance of the nasogastric aspiration and lavage for predicting upper GI bleeding is poor. The sensitivity ...
  35. [35]
    Diagnosis of gastrointestinal bleeding: A practical guide for clinicians
    Upper GI bleeding usually presents with hematemesis (vomiting of fresh blood), “coffee-ground” emesis (vomiting of dark altered blood), and/or melena (black ...
  36. [36]
    Upper gastrointestinal bleeding risk scores: Who, when and why ...
    The Rockall score should be used as a tool for identifying patients with low risk of rebleeding and death according to the clinical and endoscopic risk factors.
  37. [37]
    AIMS65: A promising upper gastrointestinal bleeding risk score but ...
    The Rockall score was designed to predict mortality and GBS for a composite of in-hospital mortality, rebleeding, endoscopic or surgical intervention and blood ...
  38. [38]
    [PDF] Endoscopic diagnosis and management of nonvariceal ... - ESGE
    Nov 16, 2015 · Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2021 ... upper gastrointestinal hemorrhage / bleeding, peptic ulcer hemorrhage ...
  39. [39]
    ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding
    For patients hospitalized with upper gastrointestinal bleeding, we suggest red blood cell transfusion at a threshold of 7 g/dL. Erythromycin infusion is ...
  40. [40]
  41. [41]
    European Society of Gastrointestinal Endoscopy (ESGE) Guideline
    Feb 10, 2021 · ESGE recommends in patients with acute upper gastrointestinal hemorrhage (UGIH) the use of the Glasgow-Blatchford Score (GBS) for pre-endoscopy risk ...
  42. [42]
    Upper Gastrointestinal Bleeding (UGIB) Treatment & Management
    Sep 1, 2021 · Current guidelines recommend a regimen of an intravenous (IV) PPI 80-mg bolus, followed by a continuous infusion of 8 mg/hour for 72 hours. Lau ...Proton-Pump Inhibitors · Bleeding Peptic Ulcer Treatment · Stress Ulcer Treatment<|separator|>
  43. [43]
    Ceftriaxone is better than norfloxacin for the prophylaxis of infections ...
    Antibiotic prophylaxis is recommended in cirrhotic patients with acute variceal bleeding. It is not known whether ceftriaxone is better than norfloxacin in ...
  44. [44]
    Anticoagulant Reversal in Gastrointestinal Bleeding - PubMed - NIH
    Anticoagulant reversal agents include prothrombin complex concentrates (PCCs; including 3 or 4 coagulation factors), plasma, vitamin K, and target-specific DOAC ...
  45. [45]
    Idarucizumab for Dabigatran Reversal in the Management of ...
    Oct 29, 2018 · Idarucizumab showed a rapid and complete reversal of dabigatran activity in nearly all patients presenting with GI bleeding, facilitating emergency patient ...Study And Follow-Up... · Dabigatran Reversal · Blood Product Management
  46. [46]
    Update on the management of upper gastrointestinal bleeding
    Sep 28, 2022 · Peptic ulcers are the most common cause of the condition. Thorough initial management with a structured approach is vital with appropriate ...<|control11|><|separator|>
  47. [47]
    Timing of Endoscopy for Acute Upper Gastrointestinal Bleeding
    Apr 1, 2020 · It is recommended that patients with acute upper gastrointestinal bleeding undergo endoscopy within 24 hours after gastroenterologic consultation.
  48. [48]
    [PDF] European Society of Gastrointestinal Endoscopy (ESGE) Guideline
    Sep 29, 2022 · intravenous erythromycin 250mg be given 30–120 min- utes prior to upper GI endoscopy in patients with suspected acute variceal hemorrhage.
  49. [49]
    Management of acute variceal bleeding: updated APASL guidelines
    Aug 31, 2025 · Terlipressin, somatostatin or octreotide are all vasoconstrictors which can be used in AVB. The choice among the vasoconstrictors may be ...
  50. [50]
    Embolization for acute nonvariceal bleeding of upper and lower ...
    Mar 29, 2023 · TAE is an effective procedure in the treatment of UGIB patients in which angiography does not demonstrate direct sign of ongoing bleeding.
  51. [51]
    Endoscopic Management of Complex Duodenal Ulcer Bleeding ...
    Jun 5, 2025 · Over‐the‐scope clips (OTSCs) are considered an effective endoscopic tool for managing upper gastrointestinal bleeding, including duodenal ulcers ...
  52. [52]
    [PDF] Severity and Outcomes of Upper Gastrointestinal Bleeding With ...
    Jan 30, 2018 · melena. In the ASGE survey from 1978 to 1979, melena was asso- ciated with a lower mortality than hematemesis (9.4 vs. 13.6%) without ...
  53. [53]
    The Importance of Rockall Scoring System for Upper ... - NIH
    Jan 14, 2016 · Rockall risk scoring system is a valuable tool to predict re-bleeding and mortality rates for patients with upper gastrointestinal bleeding in long-term ...
  54. [54]
    Role of Interventional Radiology in the Emergent Management ... - NIH
    Endoscopic predictors of rebleeding include visualized active bleeding, nonbleeding visible vessel, adherent clot, ulcer size >2 cm, and ulcer location in ...
  55. [55]
    Early esophagogastroduodenoscopy is associated with better ... - NIH
    Our study found a significant reduction in mortality associated with early EGD as compared to delayed or no EGD. A previous nationwide analysis found reduction ...
  56. [56]
    Anticoagulant Reversal in Gastrointestinal Bleeding: Review of ... - NIH
    Current guidelines generally recommend use of reversal agents in patients with serious GI bleeding on anticoagulants; patients with mild/moderate defects of ...
  57. [57]
    Clinical Factors Associated with Mortality in Cirrhotic Patients ...
    Mar 10, 2019 · Despite this, acute UGIB represents a considerable health care burden with mortality rates ranging from 15 to 30% (4–7). There is significant ...
  58. [58]
    Effects of acute kidney injury on clinical outcomes in patients with ...
    Aim: Upper gastrointestinal bleeding (UGIB) is a very frequently encountered condition that has a high morbidity and which increases treatment costs.
  59. [59]
    Risk of aspiration pneumonia in suspected variceal hemorrhage
    We conclude that in patients with suspected variceal bleeding, elective intubation is associated with a substantial risk of aspiration pneumonia.
  60. [60]
    Transfusion-related acute lung injury in ICU patients admitted with ...
    TRALI is common in critically ill ESLD patients with gastrointestinal bleeding. Nonleukoreduced red blood cells and FFP are significant transfusion-specific ...
  61. [61]
    Endoscopic treatment of bleeding peptic ulcer - PubMed
    When successful, the endoscopic methods are equally safe (associated with a risk of perforation less than 2%), although a rebleeding rate of 10-30% is of ...Missing: upper GI
  62. [62]
    Incidence of Post-ERCP Pancreatitis in Patients Receiving Rectal ...
    Aug 31, 2024 · Abstract · Background and aims: Endoscopic retrograde cholangiopancreatography (ERCP) carries a 3-15% risk of post-ERCP pancreatitis (PEP).
  63. [63]
    Transcatheter Arterial Embolization in Lower Gastrointestinal Bleeding
    Post embolization ischemia was the most common single complication seen in nine (17%). The mortality rate was 6%. Survival estimates of 1 and 5 years were 79 ...
  64. [64]
    Management of gastrointestinal bleeding in patients with cirrhosis of ...
    Initial treatment is aimed at achieving hemostasis and preventing bleeding-related complications such as renal failure, infection, and hepatic decompensation.